

Tempus Pixel Breast

AI-enabled solution to screen, detect, and track changes in lesions suspected of breast cancer

Tempus Pixel provides advanced analysis and automated reporting from routine 2D and 3D mammograms to help improve efficiency and accuracy in detecting and longitudinal tracking of changes in lesions suspected of breast cancer.

BENEFITS

Breast lesions identification

Automatically detects lesions suspected of breast cancer in 2D and 3D mammograms^{1,2}

Density assessment

Automatically generates reports that adhere to BI-RADS® tissue density categories from mammograms to help provide consistent breast anatomy assessments³

Improved accuracy when incorporating priors

The goal of incorporating priors is to evaluate lesion evaluation over time. The score may change based on the evolution or stability of the lesion. The overall accuracy of MammoScreen® improves when incorporating priors⁴


Worklist flagging

Automatically flags patient cases where the algorithm showed a higher confidence of a malignant finding, helping providers to timely review screening 2D and 3D breast images²


CONNECT WITH TEMPUS

tempus.com/radiology/tempus-pixel-breast/ ➔


BREAST LESIONS IDENTIFICATION



DENSITY ASSESSMENT



IMPROVED ACCURACY WHEN INCORPORATING PRIORS



PATIENT CONSIDERATIONS

- ✓ Female breast analysis
- ✓ Patients without surgery, pacemaker, prosthesis or implants; no prior breast cancer history. Women should not be pregnant or lactating at the time of the mammogram
- ✓ Images must have appropriate image quality and synthetic 2D images only cannot be used
- ✓ Works with digital 2D and 3D bilateral mammograms in DICOM format with 2 standard views (mediolateral oblique and craniocaudal)

¹ Conant EF, Toledano AY, Periaswamy S, et al. Improving accuracy and efficiency with concurrent use of artificial intelligence for digital breast tomosynthesis. *Radiology: Artificial Intelligence*. 2019;1(4):e180096. <https://doi.org/10.1148/ryai.2019180096>

² Tempus Pixel is FDA-cleared ([K203744](#)) and CE marked; detection of lesions suspected of breast cancer is powered by iCAD's ProFound AI ([K203822](#)). Arterys Inc is the manufacturer of Tempus Pixel, excluding any third party components described in this list. iCAD is the manufacturer of ProFound AI.

³ Breast density assessment is powered by iCAD's ProFound AI ([K203822](#)). iCAD is the manufacturer of the Breast density assessment.

⁴ Tempus Pixel is FDA-cleared ([K203744](#)) and CE Marked. Therapixel is the manufacturer of MammoScreen® ([K211541](#)) which incorporates priors in its cancer detection analysis. Arterys Inc is the manufacturer of Tempus Pixel, excluding any third party components described in this list.